Woodstock Research Center
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Manchon, Jose
NCT04693351 / 2020-004653-69: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Active, not recruiting
3
700
Europe, Canada, US, RoW
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
04/25
04/25
Buch, Bárbara
NCT04693351 / 2020-004653-69: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Active, not recruiting
3
700
Europe, Canada, US, RoW
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
04/25
04/25
Balenger, Brenda
NCT04693351 / 2020-004653-69: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Active, not recruiting
3
700
Europe, Canada, US, RoW
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
04/25
04/25
NCT05407064: A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

Completed
2
198
US
MM-120 (LSD D-Tartrate), Placebo
Mind Medicine, Inc.
Anxiety Generalized
10/23
11/23
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30

Download Options